GlassScriptPhysician profile
Imane Abdelmoumen
NPI 1518348051
$6,777.71
in general payments reported to CMS, 2019-2025
30 companies · $2,162 in 2025
The $2,162 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $333 · 2022: $1,257 · 2023: $1,118 · 2024: $1,908 · 2025: $2,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,417 · Travel and Lodging: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,416.96 |
| Travel and Lodging | $770.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,272.95 | 2022-2025 | Fintepla, Briviact, Nayzilam |
| Livanova USA, INC. | $1,457.51 | 2024-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $779.17 | 2022-2025 | |
| Neurelis, INC. | $681.38 | 2021-2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $261.30 | 2024-2025 | Motpoly Xr |
| Sk Life Science, INC. | $191.62 | 2025 | |
| Aquestive Therapeutics, INC. | $174.30 | 2021-2024 | |
| Tris Pharma INC | $110.03 | 2022-2025 | Onyda Xr |
| Supernus Pharmaceuticals, INC. | $109.66 | 2021-2023 | Qelbree, Oxtellar Xr |
| Corium, LLC | $92.69 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $73.97 | 2025 | Daybue |
| Eisai INC. | $62.66 | 2022 | |
| Greenwich Biosciences, INC. | $61.64 | 2021 | |
| Biogen, INC. | $57.16 | 2022-2024 | Skyclarys |
| Sunovion Pharmaceuticals INC. | $56.58 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aprecia Pharmaceuticals, LLC | $45.43 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $30.95 | 2023 | Lyvispah |
| Azurity Pharmaceuticals, INC. | $30.02 | 2022 | |
| Orchard Therapeutics North America | $28.12 | 2025 | Lenmeldy |
| Baxter Healthcare | $27.56 | 2023 | Hillrom - Synclara Cough System |
| Ns Pharma, INC. | $25.93 | 2025 | Viltepso |
| Medtronic, INC. | $22.12 | 2023 | Synchromedii |
| Tersera Therapeutics LLC | $21.47 | 2022 | |
| Sarepta Therapeutics, INC. | $21.07 | 2021 | |
| Ptc Therapeutics, INC. | $21.02 | 2021 | |
| Collegium Pharmaceutical, INC. | $17.57 | 2025 | Jornay Pm |
| Zogenix INC. | $17.46 | 2021 | |
| Biomarin Pharmaceutical INC. | $11.78 | 2022 | |
| Metacel Pharmaceuticals LLC | $10.29 | 2022 | |
| Sumitomo Pharma America, INC. | $4.30 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imane Abdelmoumen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.